MacroGenics, Inc. MGNX was a big mover last session, as the company saw its shares rise above 5% on the day. The upside came after the company held its first R&D Day in which, an in-depth review of its broad portfolio of product candidates and technology platforms was provided. This continues the uptrend for the company since Sep 29, as the stock is now up more than 15%.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
MacroGenics carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked med products stock is Baxter International Inc. BAX, which sports a Zacks Rank #1 (Strong Buy).
Is MGNX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment